Better Buy: GW Pharmaceuticals vs. Corbus Pharmaceuticals

Don't call GW Pharmaceuticals (NASDAQ: GWPH) and Corbus Pharmaceuticals (NASDAQ: CRBP) "pot stocks." These legitimate drug developers seek to harness the body's endocannibinoid pathways to treat serious diseases.   

GW made headlines in 2018 when the Food and Drug Administration (FDA) approved Epidiolex, the first cannabis-derived drug. European regulators gave their stamp of approval for the drug, a treatment for rare pediatric seizures, last September. The market confirmed the patient need for Epidiolex, and GW sold nearly $300 million worth of the drug.

Image source: Getty Images.

Continue reading

Source Fool.com